PER
Click for more information
1.23% 8.0¢ percheron therapeutics limited

atl1102 a clear winner, page-5

  1. skyrocketer
    1,496 Posts.
    clock Created with Sketch.
    20/01/12
    13:06
    Post #: 9576888
    In the ann dated 20 Sept 2011 on ATL1102, ANP stated the comparison value of another Stem Cell Mobilisation therapy, Mobobil:

    "One such complimentary therapy, Mozobil, has been approved for use in combination with the main agent G-CSF. First marketed in 2009, MozobilTM sales in 2010 were ~US$100Mill with peak sales potential estimated at US$350Mill per annum."
    ANP Price at posting: 25.0¢ Sentiment: LT Buy Disclosure: Held
    Likes Created with Sketch. 5  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

OBM Ora Banda sees FY26 gold output jumping to 150Koz/pa following key approval for Sand King
right-arrow Created with Sketch.
RNU Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
right-arrow Created with Sketch.
SKS SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne
right-arrow Created with Sketch.
NEWS ASX hits all time high out the gate on Friday trades following bullish US inflation data
right-arrow Created with Sketch.
GED Golden Deeps eyes prospective Cu-Au tenements in NSW with HOA
right-arrow Created with Sketch.
NEWS What matters for FY25: Investment; interest rates; inflation & elections
right-arrow Created with Sketch.
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.0¢ 		Change
-0.001(1.23%) 		Mkt cap ! $72.12M
Open High Low Value Volume
8.2¢ 8.2¢ 8.0¢ $63.52K 777.8K

Buyers (Bids)

No. Vol. Price($)
2 43377 8.0¢
 

Sellers (Offers)

Price($) Vol. No.
8.2¢ 97561 1
View Market Depth
Last trade - 16.10pm 12/07/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.